Epcoritamab Shows Durable Responses in Large B-Cell Lymphoma Trials
At the 66th Annual Meeting of the American Society of Hematology (ASH), AbbVie shared new data from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody. Administered subcutaneously,…
Pozelimab-Cemdisiran Combo Surpasses Ravulizumab in Controlling PNH Hemolysis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced updated Phase 3 data from the ACCESS-1 trial, showing that its investigational combination of pozelimab and cemdisiran (poze-cemdi) outperforms the standard-of-care C5 inhibitor, ravulizumab,…
Kite Presents New Data on Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH
Kite, a Gilead Company presented new findings from three analyses on Yescarta® (axicabtagene ciloleucel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) at the 66th Annual Meeting & Exposition…
Epcoritamab Combination Therapy Shows High Response Rates in R/R Follicular Lymphoma Trial
Genmab has announced promising results from the Phase 1b/2 EPCORE® NHL-2 trial, which evaluated a fixed-duration regimen of epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab…
Epcoritamab Monotherapy Shows High Response Rates in R/R CLL Trial
Genmab has announced promising results from the Phase 1b/2 EPCORE® CLL-1 clinical trial evaluating epcoritamab, a T-cell engaging bispecific antibody, in patients with relapsed or refractory chronic lymphocytic leukemia (R/R…
Incyte Reports Positive Phase 3 Results for Retifanlimab in NSCLC
Incyte has announced promising results from the Phase 3 POD1UM-304 trial evaluating retifanlimab (Zynyz®), a PD-1-targeting monoclonal antibody, in combination with platinum-based chemotherapy for adults with previously untreated metastatic non-small…
Blueprint Medicines Showcases Leadership in Systemic Mastocytosis at 2024 ASH Meeting
Blueprint Medicines Corporation presented compelling new data at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the long-term benefits of AYVAKIT® (avapritinib) in treating systemic mastocytosis (SM). These…
AbbVie Releases Report on Mental Health in Underrepresented CLL Patients
AbbVie has unveiled key findings from its latest Emotional Impact Report (EIR), offering insights into the mental health challenges faced by patients with chronic lymphocytic leukemia (CLL). For the first…
An Innovative Approach to Efficient Anti-Cancer Drug Synthesis
The Horner-Wadsworth-Emmons (HWE) reaction is a fundamental reaction in organic chemistry, widely used to create conjugated carbonyl compounds. Conjugated carbonyl compounds are used in many industries for synthesizing perfumes, plastics,…
Stoke Therapeutics Presents Data Supporting Zorevunersen as Treatment for Dravet Syndrome
Stoke Therapeutics has announced new data from its Phase 1/2a and open-label extension (OLE) studies on zorevunersen, a potential disease-modifying treatment for Dravet syndrome. The data revealed significant and lasting…
Alithea Genomics Unveils Full-Length DRUG-Seq to Enhance Transcriptomics in Drug Discovery
Alithea Genomics, a leading innovator in large-scale RNA sequencing and transcriptomics, has unveiled its latest technological advancement: the MERCURIUS™ Full-Length DRUG-seq library preparation platform. This new solution represents a groundbreaking…
Children’s Hospital Los Angeles Marks 100th Retinal Gene Therapy Procedure
At Children’s Hospital Los Angeles Dr. Aaron Nagiel, MD, PhD, has witnessed firsthand the profound impact of retinal gene therapy on children with Leber congenital amaurosis (LCA), a rare genetic…